Legal Guidance and Research / Experts / Charlie French
Charlie French#7376
LinkedIn

Charlie French

Bristows
Charlie specialises in contentious intellectual property matters. She has a particular interest in patent litigation in the pharmaceutical and biotechnology sectors, where her background in biochemistry gives her an excellent understanding of the technical issues that arise. She has also advised on the enforcement of plant variety rights, including customs seizures.
 
Charlie has extensive experience representing clients in complex litigation before the Patents Court (High Court) and Court of Appeal, as well as assisting parties in relation to arbitral disputes. She also works closely with lawyers, patent attorneys and regulatory advisors in multiple jurisdictions to coordinate global patent litigation strategies and life-cycle management for pharmaceutical and biotechnology products.
 
Within the life sciences sector, Charlie has advised on disputes relating to small molecule pharmaceuticals, antibodies and antibody engineering technology, gene cloning and cell-based expression systems, drug delivery systems, formulations and dosage regimens. Charlie has also assisted clients in relation to disputes in the fields of shipping, software development and agriculture.

Practice Area

Panel

  • Contributing Author

Qualified Year

  • 2012

Experience

  • Linklaters LLP (2010 - 2014)

Membership

  • AIPPI
  • IPSoc

Qualifications

  • MA Natural Sciences (Biochemistry), University of Cambridge (2006)
  • LLB BPP Law School (2009)
  • Legal Practice Course, College of Law (2009)
  • Postgraduate Diploma in Intellectual Property Law & Practice, University of Oxford (2013)

Education

  • University of Cambridge (2003-2006)
  • BPP Law School (2007-2009)
  • College of Law (2008-2009)
  • University of Oxford (2012-2013)

1 Contributions by Charlie French

UK patent research exemptions: experimental use and Bolar-type, plus the SPC manufacturing waiver - post-Brexit position and practical points
PRACTICE NOTES
UK patent research exemptions: experimental use and Bolar-type, plus the SPC manufacturing waiver - post-Brexit position and practical points
Practice Note Patent regimes are designed to encourage innovation rather than obstruct it. Consequently, the patent laws of numerous jurisdictions provide carve-outs from infringement for experimental use of patented inventions. This Practice Note reviews the two principal UK research exemptions to patent infringement, namely: the general experimental use exemption the specific Bolar-type exemption It considers how these provisions have evolved in recent years and how they may develop in the coming period. The Note also addresses the supplementary protection certificate (SPC) manufacturing waiver, which creates an exception to infringement of SPCs (SPCs extend patent protection for certain medicinal products). Following Brexit, EU-derived legislation has been preserved and converted into UK domestic law with effect from IP completion day (11 pm on 31 December 2020). Relevant Assimilated EU law and Brexit SIs are considered in the sections on the Bolar-type exemption and the SPC manufacturing waiver. ‘Assimilated law’ is the term used for retained EU law (REUL) that remains in force after the end of 2023...
Life Sciences
Expert page AD
If you expected to see yourself on this page, click here.